Goodwin Procter·IP / PATENT

Takeda Sues Polpharma Over Vedolizumab Biosimilar in First BPCIA Case

Takeda has filed a BPCIA complaint in New Jersey federal court against Polpharma Biologics, alleging that its vedolizumab biosimilar PB016 infringes six patents related to ENTYVIO, marking the first such case involving this biologic drug.

bpcia-litigationvedolizumab-biosimilarpatent-infringementtakeda-pharmaceuticalspolpharma-biologicsentyvio-patent
Read the original firm alert → Wednesday, September 2, 2026

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.